Bevacizumab T9904
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with h
CAS nr:
216974-75-3
Purity:
98%
Molecular Weight:
149000
SMILES:
Formula:
Pathway:
Tyrosine Kinase/Adaptors,Angiogenesis
Target:
VEGFR,VEGFR
